CCR2 and cancer: Small-molecule antagonists against CCR2/CCR5 have been investigated in certain types of cancer, and only BMS-813160 is in a phase 2 study (NCT04123379), which has been applied to non-small cell lung cancer and hepatocellular carcinoma.